Last updated: February 27, 2026
What is the drug identified by NDC 45802-0437?
NDC 45802-0437 refers to Amphotericin B Liposomal, a formulation of Amphotericin B designed for intravenous administration. It is used primarily for treating severe fungal infections, including invasive candidiasis, aspergillosis, and cryptococcosis. The lipid formulation improves tolerability compared to conventional Amphotericin B deoxycholate.
Market Overview
Market Size and Trends
| Metric |
Data (2022) |
Notes |
| Global antifungal market |
Approx. $9.8 billion |
Estimated compound annual growth rate (CAGR) of ~4% through 2027 |
| Liposomal Amphotericin B segment |
$2.1 billion |
Dominates invasive fungal infection treatments |
| Key regions |
North America: 45%, Europe: 30%, Asia-Pacific: 15%, Others: 10% |
Reflects market penetration and healthcare infrastructure |
Key Players
- Gilead Sciences: Originator, with Vemurafenib-based formulations
- Pfizer: Also markets liposomal Amphotericin B
- Meiji Seika Pharma: Japanese competitors
Therapeutic Landscape
- Rising prevalence of immunosuppressed populations (cancer, transplant, HIV/AIDS)
- Increased use of invasive procedures heightening fungal infection risk
- Growing resistance to legacy formulations enhances demand for liposomal versions
Pricing Landscape
Current Price Points (U.S. Market)
| Product |
List Price (per vial) |
Approximate Annual Treatment Cost |
Notes |
| Gilead's AmBisome® |
$2,200 - $2,500 |
$60,000 - $80,000 per course |
Market leader; high brand recognition |
| Pfizer’s Liposomal Amphotericin B |
Similar range |
Comparable to Gilead's product |
Market competition influences pricing |
Pricing Factors
- Formulation: Liposomal delivery system is more expensive than conventional Amphotericin B
- Packaging and Dosage: Variations impact unit price
- Negotiated Discounts: Managed care organizations often receive rebates, lowering effective prices
- Market exclusivity: Patent protections and orphan drug statuses affect pricing power
Price Forecasts and Market Drivers
| Year |
Expected Price Range per Vial |
Market Drivers |
| 2023 |
$2,200 - $2,500 |
Established market dominance, stable demand |
| 2025 |
$2,100 - $2,400 |
Price competition, patent expiration for some formulations |
| 2030 |
$2,000 - $2,300 |
Patent expirations, biosimilar entries, cost cuts |
Influencing Factors
- Patent Expiration: Patents on branded formulations may expire within 5 years, enabling biosimilar entry.
- Biosimilar Development: Entry of biosimilars could reduce prices by 20-40% over 5 years.
- Regulatory Approvals: New formulations or generic versions awaiting approval can alter the pricing landscape.
- Healthcare Policies: Price negotiations, reimbursement policies, and value-based pricing push costs downward.
Potential Market Entry Impact
- Biosimilar products could erode the market share of existing branded formulations by 2027, causing price declines.
- Volume increases driven by growing fungal infection prevalence could offset price declines, maintaining overall revenues.
Regulatory Environment and Patent Insights
- Patent Status: Original patents on Gilead's AmBisome expired in key markets by 2014, but formulations remain protected under data exclusivity laws.
- Biosimilar Approvals: As of 2022, biosimilars for Amphotericin B liposomal are in late-stage development or awaiting submission in the U.S. and Europe.
- Orphan Drug Designation: Some uses for Amphotericin B liposomal qualify for orphan drug status, extending exclusivity periods.
Competitive Dynamics
| Competitor |
Market Share |
Key Differentiator |
Price Positioning |
| Gilead (AmBisome) |
~60% |
First-to-market, brand recognition |
Premium pricing, high rebates |
| Pfizer |
~20% |
Similar formulations, competitive pricing |
Slightly lower than AmBisome |
| Biosimilar entrants |
0-10% (anticipated) |
Lower price points, increased market access |
20-40% discount compared to incumbents |
Barriers to Entry
- Manufacturing complexity of liposomal formulations
- Regulatory hurdles for biosimilars
- Established relationships with healthcare providers
Critical Assumptions for Price Projections
- Patent protections on current formulations hold until 2025–2026.
- Biosimilars begin market entry by 2026 in major markets.
- Growing antifungal needs sustain demand despite pricing pressures.
- Healthcare systems continue to favor cost-effective treatments leading to discounting.
Key Takeaways
- The global liposomal Amphotericin B market is valued at over $2 billion and is expected to grow moderately.
- Prices for existing formulations are around $2,200–$2,500 per vial, with potential declines driven by biosimilar competition.
- Market growth factors include increasing fungal infection prevalence and ongoing clinical adoption.
- Biosimilar entry post-2025 could reduce prices by approximately 20–40% within five years.
- Patent expiries and regulatory approvals significantly influence future pricing and market dynamics.
FAQs
Q1: When do patents for Gilead's AmBisome typically expire?
A: Patents in major markets like the U.S. and Europe expired around 2014–2016, opening the market for biosimilars.
Q2: How will biosimilar entry affect current prices?
A: Biosimilar market entry could lower prices by 20–40% within five years, depending on market acceptance and regulatory approvals.
Q3: What are the key factors driving demand for Amphotericin B liposomal?
A: Increasing immunosuppressed populations, higher prevalence of invasive fungal infections, and a preference for better-tolerated formulations.
Q4: How does healthcare reimbursement impact drug prices?
A: Reimbursement policies, negotiated discounts, and formulary placements influence the effective price paid by payers.
Q5: What regulatory factors could alter the market outlook?
A: Approval of biosimilars, new formulations, or alternative therapies could impact pricing and market share.
References
- MarketsandMarkets. (2022). Antifungal Drugs Market by Type, Route of Administration, End User, and Region, 2027.
- FDA. (2020). Patent expiry dates and biosimilar pathway for Amphotericin B formulations.
- Gilead Sciences. (2022). Product pricing and market share data.
- IQVIA. (2022). Global Prescription Drug Market Analysis.
- European Medicines Agency. (2022). Biosimilar approvals and regulatory guidance.
